Peck-Radosavljevic M
Department of Gastroenterology and Hepatology, Medizinische Universität & AKH Wien, Vienna, Austria.
Aliment Pharmacol Ther. 2007 Nov;26 Suppl 1:21-8. doi: 10.1111/j.1365-2036.2007.03509.x.
The liver is the site for synthesis of the vast majority of proteins that play a central role in maintaining hemostasis, by participating in the regulation of coagulation and fibrinolysis.
To summarize the available data on the impact of coagulation disorders in patients with chronic liver disease.
Hepatocellular damage in patients with severe liver disease can lead to abnormalities in the production and function of coagulation and fibrinolytic factors, disrupting the balance between coagulation and anticoagulation systems.
Hemostatic abnormalities (eg. impaired synthesis of clotting factors, heightened fibrinolysis, disseminated intravascular coagulation, thrombocytopenia, and platelet dysfunction) can increase the risk of bleeding in cirrhotic patients.
肝脏是绝大多数在维持止血过程中发挥核心作用的蛋白质的合成场所,这些蛋白质通过参与凝血和纤维蛋白溶解的调节发挥作用。
总结关于慢性肝病患者凝血障碍影响的现有数据。
严重肝病患者的肝细胞损伤可导致凝血和纤维蛋白溶解因子的产生及功能异常,破坏凝血和抗凝系统之间的平衡。
止血异常(如凝血因子合成受损、纤维蛋白溶解增强、弥散性血管内凝血、血小板减少和血小板功能障碍)可增加肝硬化患者出血的风险。